Theriva Biologics, Inc. - 8-K Filing
Theriva Biologics sells SYN-004 and SYN-006 product assets to Biossil Labs Inc. for $350,000 upfront plus milestone contingencies. (Items: 1.01 Entry into a Material Definitive Agreement, 2.01 Completion of Acquisition or Disposition of Assets, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $TOVX
Read the full article at SEC EDGAR
Part of the story Imunon, Inc. - 8-K Filing (38 articles)